



Investor Relations  
Phone: (301) 897-2564  
Email: [info@spherix.com](mailto:info@spherix.com)

## SPHERIX INCORPORATED HOLDS 2008 EARNINGS CONFERENCE CALL

**Bethesda, MD.** March 31, 2009 - Spherix (NasdaqCM:SPEX - News) has scheduled its 2008 earnings conference call for Thursday, April 2, 2009.

Dr. Claire Kruger, Chief Executive Officer and Director of Health Sciences; Dr. Robert Lodder, President; and Robert Clayton, Chief Financial Officer, will be hosting the conference call.

Dr. Kruger will provide an overview of Spherix and recent developments at the Company, and will then hand the call over to Robert Clayton who will discuss the 2008 financial results. Dr. Lodder and Dr. Kruger will then conclude with subsidiary updates and closing remarks.

Date: April 2, 2009  
Time: 10:00 AM ET

Listen via Internet:

Schedule this webcast into MS-Outlook calendar (click open when prompted):<http://apps.shareholder.com/PNWOutlook/t.aspx?m=36081&k=1FE334F2>

Telephone: 877-675-4753

An audio replay of the conference call will be available approximately one hour after the call on the Spherix website at <http://spherix.com/corpEventCal.html>.

Spherix Incorporated was launched in 1967 as a scientific research company, under the name Biospherics Research. The company now leverages its scientific and technical expertise and experience through its two subsidiaries -- Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is currently running a Phase 3 clinical trial to study the use of Naturlose as a treatment for Type 2 diabetes. Its Spherix Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides. For more information, please visit <http://www.spherix.com>.

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of Naturlose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop Naturlose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our current report on Form 8-K filed on October 10, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.